April 14, 2025

FDA-Approved COVID-19 Drugs: Safety Risks Assessed

Researchers found most FDA-authorized COVID-19 treatments were not linked to serious adverse events, though risks may rise with tocilizumab or convalescent plasma in specific patients.

Conexiant

April 11, 2025

Early Antibiotics Linked to Asthma, Eczema

Researchers found early-life antibiotic use was linked to increased risk of asthma and eczema, but not most other immune diseases, after adjusting for familial factors.

Conexiant

April 10, 2025

Study: LLMs Show Biases in Medical Decision-Making

Large language models recommend different care based on patients' race, housing status, income level, and sexual orientation, potentially amplifying health care disparities if deployed without safeguards, researchers find.

Conexiant

April 09, 2025

Oral Microbiome Linked to Chronic Pain in Women

Study finds poor oral health and oral pathobionts associated with pain in migraine, fibromyalgia, and abdominal disorders, suggesting possible treatment avenues.

Conexiant

April 09, 2025

Secukinumab Shows Long-Term Efficacy in HS

Secukinumab demonstrated sustained clinical benefits, with 76.5% of patients maintaining hidradenitis suppurativa clinical response at week 104, study shows.

Conexiant

April 08, 2025

Study Investigates Efficacy of Baricitinib Tapering

Most patients maintained control of disease activity after tapering baricitinib, according to the RA-BEYOND study.

Conexiant

April 08, 2025

Link Between Gut Microbiota and Skin Inflammation Uncovered

IL-15RA mediated 11% of the pathway between Veillonellaceae and eczema, supporting a role for inflammatory proteins in the gut-skin axis.

Conexiant

April 04, 2025

First IgG4-RD Treatment Approved

A humanized monoclonal antibody that targets CD19+ B cells is first FDA-approved treatment for immunoglobulin G4–related disease, reducing flare risk and glucocorticoid use in clinical trials.

Conexiant

April 02, 2025

Cost-Effectiveness of Shoulder Arthroplasties Analyzed

Total shoulder arthroplasty was found to be more cost-effective than hemiarthroplasty.

Conexiant